This clinical practice guideline from the American Heart Association (AHA) aims to give healthcare providers consistent, clear, and evidence-based guidance for treating patients at risk for atherosclerotic cardiovascular disease (ASCVD)
AHA cholesterol management guideline for healthcare practitioners
American Heart Association (AHA), 2018
This clinical practice guideline from the American Heart Association (AHA) aims to give healthcare
providers consistent, clear, and evidence-based guidance for treating patients at risk for atherosclerotic
cardiovascular disease (ASCVD).
The guidance covers risk assessment, primary and secondary prevention of ASCVD, lifestyle
interventions, statin therapy, and non-statin alternatives and adjuncts. It also includes printable tools to help:
- Assess patients’ risk for ASCVD and the use of tools such as the ASCVD risk calculator
- Understand when and how to prescribe and manage statins and non-statin therapies
- Discuss a patient’s ASCVD risks as well as options for treatment
- Overcome common barriers to treatment
The authors highlight that, for primary prevention of ASCVD, fasting and non-fasting total cholesterol and HDL-C levels have similar prognostic value and associations with CVD outcomes. Therefore, recommendations are to measure either a fasting or a non-fasting plasma lipid profile to estimate ASCVD risk and document baseline LDL-C in adults who are 20 years or older and not on lipid-lowering therapy. Point-of-care lipid testing (and screening), as a result, can be used in place of traditional fasting laboratory lipid tests, where there is potential clinical benefit.
The guidelines can be accessed here.
&copia; 2022 Abate. Tutti i diritti riservati. Tutti i marchi citati sono marchi del gruppo di società Abbott o dei rispettivi proprietari.
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessmentenAccedi ora
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney diseaseenAccedi ora